Advanced search

Vol 81, Supp. I (2023): Zeszyty Edukacyjne 1/2023
Opinie i stanowiska ekspertów
Published online: 2023-09-27

open access

View PDF (Polish) Download PDF file
Page views 458
Article views/downloads 291
Get Citation

Connect on Social Media

Connect on Social Media

Znaczenie szczepień przeciwko pneumokokom w redukcji ryzyka sercowo-naczyniowego pacjentów kardiologicznych. Opinia ekspertów Komisji Profilaktyki Polskiego Towarzystwa Kardiologicznego wsparta przez Polskie Towarzystwo Wakcynologiczne

Artur Mamcarz1, Marcin Wełnicki1, Jarosław Drożdż2, Marcin Grabowski3, Piotr Jankowski4, Ernest Kuchar5, Przemysław Leszek6, Przemysław Mitkowski7, Jacek Wysocki8
DOI: 10.33963/v.kp.96988

Abstract

Choroby układu oddechowego stały się w ostatnich latach czwartą najczęstszą przyczyną zgonów w Polsce. Infekcja dróg oddechowych, zwłaszcza zapalenie płuc, może prowadzić do zaostrzenia przewlekłej choroby układu krążenia. Streptococcus pneumoniae jest najczęstszym bakteryjnym patogenem powodującym pozaszpitalne zapalenie płuc. Pneumokoki są również najczęstszym patogenem wikłającym przebieg grypy. Zapalenie płuc, zwłaszcza inwazyjna choroba pneumokokowa, wiąże się z ryzykiem zgonu w przebiegu niewydolności oddechowej lub posocznicy, a także z pogorszeniem rokowania istniejącej choroby układu krążenia. Pomimo to zalecenia dotyczące szczepienia przeciwko pneumokokom nadal nie są dobrze ugruntowane w wytycznych kardiologicznych. Celem niniejszego dokumentu jest podsumowanie aktualnej wiedzy na temat znaczenia profilaktyki inwazyjnej choroby pneumokokowej w kontekście pacjentów z chorobami układu sercowo-naczyniowego.

Keywords: inwazyjna choroba pneumokokowapozaszpitalne zapalenie płucschorzenia układu sercowo-naczyniowegoszczepienie przeciwko pneumokokom

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. CSO: mortality in 2021, death by cause. Preliminary data [in Polish]. https://stat.gov.pl/obszary-tematyczne/ludnosc/statystyka-przyczyn-zgonow/umieralnosc w-2021-roku-zgony-wedlug-przyczyn-dane-wstepne,10,3.html (21.11.2022).
  2. Polish Ministry of Health. Health Needs Maps: Database of System and Implementation Analysis [in Polish]. http://www.mpz.mz.gov.pl (Lipiec 2022).
  3. Ieven M, Coenen S, Loens K, et al. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. Clin Microbiol Infect. 2018; 24(11): 1158–1163.
    CrossRefPubMed
  4. Antczak A, Tworek D. Pneumonia in adults [in Polish]. Termedia, Poznań 2022.
  5. Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses. 2016; 10(5): 394–403.
    CrossRefPubMed
  6. Devine VT, Cleary DW, Jefferies JMC, et al. The rise and fall of pneumococcal serotypes carried in the PCV era. Vaccine. 2017; 35(9): 1293–1298.
    CrossRefPubMed
  7. Siegel SJ, Roche AM, Weiser JN. Influenza promotes pneumococcal growth during coinfection by providing host sialylated substrates as a nutrient source. Cell Host Microbe. 2014; 16(1): 55–67.
    CrossRefPubMed
  8. Mastalerz-Migas A, Kuchar E, Nitsch-Osuch A, et al. Recommendations for the prevention, diagnosis and treatment of inFLUenza in adults for Primary care physiciAnS: FLU COMPAS PCP – ADULTS. Family Medicine & Primary Care Review. 2020; 22(1): 81–96.
    CrossRef
  9. Pająk A, Jankowski P, Zdrojewski T. The burden of cardiovascular disease risk factors: A current problem. Kardiol Pol. 2022; 80(1): 5–15.
    CrossRefPubMed
  10. Violi F, Pignatelli P, Cammisotto V, et al. COVID-19 and thrombosis: Clinical features, mechanism of disease, and therapeutic implications. Kardiol Pol. 2021; 79(11): 1197–1205.
    CrossRefPubMed
  11. Tadic M, Cuspidi C. In-hospital outcomes in COVID-19 patients: Did we learn something? Kardiol Pol. 2021; 79(7-8): 730–732.
    CrossRefPubMed
  12. Jankowska-Sanetra J, Sanetra K, Konopko M, et al. Incidence and course of acute coronary syndrome cases after the first wave of the COVID-19 pandemic. Kardiol Pol. 2023; 81(1): 22–30.
    CrossRefPubMed
  13. Zhu X, Ge Y, Wu T, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020; 285: 198005.
    CrossRefPubMed
  14. Said MA, Johnson HL, Nonyane BAS, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8(4): e60273.
    CrossRefPubMed
  15. Jansen AG, Rodenburg GD, van der Ende A, et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis. 2009; 49(2): e23–e29.
    CrossRefPubMed
  16. Centers for Disease Control and Prevention. Active Bacterial Core surveillance (ABCs) report. Emerging Infections Program Network: Streptococcus pneumoniae, 2012. www.cdc.gov/abcs/reports-findings/survreports/spneu12.pdf (Grudzień 2022).
  17. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2010; 59(34): 1102–1106.
  18. Musher DM. Streptococcus pneumoniae. In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. 2010: 2623–2642.
  19. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect. 2012; 65(1): 17–24.
    CrossRefPubMed
  20. Klemets P, Lyytikäinen O, Ruutu P, et al. Invasive pneumococcal infections among persons with and without underlying medical conditions: implications for prevention strategies. BMC Infect Dis. 2008; 8: 96.
    CrossRefPubMed
  21. Centers for Disease Control and Prevention. Prevention of pneumococcal infections secondary to seasonal and 2009 H1N1 influenza viruses infection. www.cdc.gov/h1n1flu/vaccination/provider/provider_pneumococcal.htm (Grudzień 2022).
  22. Skoczyńska A, Gołębiewska A, Wróbel-Pawelczyk I, et al. Invasive pneumococcal disease in Poland in 2021 [in Polish]. KOROUN 2022.
  23. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017; 65(11): 1806–1812.
    CrossRefPubMed
  24. Curcio D, Cané A, Isturiz R. Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis. 2015; 37: 30–35.
    CrossRefPubMed
  25. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014; 1(1): ofu024.
    CrossRefPubMed
  26. The report "Pneumococcal pneumonia in adults: The situation in Poland. Epidemiology, consequences, prevention" [in Polish] prepared in June 2021 by HealthQuest Ltd. https://pneumokokinieliczalat.pl (Grudzień 2022).
  27. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015; 313(3): 264–274.
    CrossRefPubMed
  28. Bergh C, Fall K, Udumyan R, et al. Severe infections and subsequent delayed cardiovascular disease. Eur J Prev Cardiol. 2017; 24(18): 1958–1966.
    CrossRefPubMed
  29. Eurich DT, Lee C, Marrie TJ, et al. Inhaled corticosteroids and risk of recurrent pneumonia: a population-based, nested case-control study. Clin Infect Dis. 2013; 57(8): 1138–1144.
    CrossRefPubMed
  30. Africano HF, Serrano-Mayorga CC, Ramirez-Valbuena PC, et al. Major adverse cardiovascular events during invasive pneumococcal disease are serotype dependent. Clin Infect Dis. 2021; 72(11): e711–e719.
    CrossRefPubMed
  31. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Kardiol Pol. 2015; 73(12): 1127–1206.
    CrossRefPubMed
  32. Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022; 43(38): 3618–3731.
    CrossRefPubMed
  33. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(29): 2315–2381.
    CrossRefPubMed
  34. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022; 29(1): 5–115.
    CrossRefPubMed
  35. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
    CrossRefPubMed
  36. Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020; 99: 204–213.
    CrossRefPubMed
  37. Ren S, Newby D, Li SC, et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart. 2015; 2(1): e000247.
    CrossRefPubMed
  38. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015; 22(9): 1185–1199.
    CrossRefPubMed
  39. Chang YC, Chou YJ, Liu JY, et al. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan--a representative population-based comparative study. J Infect. 2012; 65(3): 231–238.
    CrossRefPubMed
  40. Zahid M, Singla I, Good CB, et al. Associations between pneumococcal vaccinationand adverse outcomes in patients with suspected acute coronary syndrome. Advances in Infectious Diseases. 2012; 02(04): 122–134.
    CrossRef
  41. Eurich DT, Johnstone JJ, Minhas-Sandhu JK, et al. Pneumococcal vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. Heart. 2012; 98(14): 1072–1077.
    CrossRefPubMed
  42. Jaiswal V, Ang SP, Lnu K, et al. Effect of pneumococcal vaccine on mortality and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Med. 2022; 11(13).
    CrossRefPubMed
  43. Ren S, Hure A, Peel R, et al. AUSPICE study group. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016; 177: 58–65.
    CrossRefPubMed
  44. Ren S, Hansbro PM, Srikusalanukul W, et al. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis. 2022; 346: 68–74.
    CrossRefPubMed
  45. Nilsson J, Hansson GK. Vaccination strategies and immune modulation of atherosclerosis. Circ Res. 2020; 126(9): 1281–1296.
    CrossRefPubMed
  46. Clutterbuck EA, Lazarus R, Yu LM, et al. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. J Infect Dis. 2012; 205(9): 1408–1416.
    CrossRefPubMed
  47. Pletz MW, Maus U, Krug N, et al. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents. 2008; 32(3): 199–206.
    CrossRefPubMed
  48. Announcement of the Chief Sanitary Inspector dated October 28, 2021 on the 2022 Immunization Program [in Polish].
  49. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. Vaccine. 2013; 31(35): 3594–3602.
    CrossRefPubMed
  50. van Werkhoven CH, Huijts SM, Bolkenbaas M, et al. The impact of age on the efficacy of 13-valent pneumococcal conjugate vaccine in elderly. Clin Infect Dis. 2015; 61(12): 1835–1838.
    CrossRefPubMed
  51. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design. Clin Infect Dis. 2018; 67(10): 1498–1506.
    CrossRefPubMed
  52. Niederman MS, Folaranmi T, Buchwald UK, et al. Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. Expert Rev Vaccines. 2021; 20(3): 243–256.
    CrossRefPubMed
  53. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015; 372(12): 1114–1125.
    CrossRefPubMed
  54. Characteristics of the Medicinal Product Pneumovax 23 [in Polish]. Date of last update July 9, 2019.
  55. Apexxnar Product Characteristics [in Polish].
  56. Product Characteristics of Prevenar 13 [in Polish]. Date of last update: November 25, 2020.
  57. European Centre for Disease Prevention and Control (ECDC). Monitor Atlas of Infectious Diseases, Invasive Pneumococcal Disease, 2018. https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2018_IPD.pdf (18.04.2021).
  58. Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. PLoS One. 2017; 12(5): e0177113.
    CrossRefPubMed
  59. Hausdorff WP, Hanage WP. Interim results of an ecological experiment - Conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016; 12(2): 358–374.
    CrossRefPubMed
  60. Moore MR, Link-Gelles R, Schaffner W, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015; 15(3): 301–309.
    CrossRefPubMed
  61. Metcalf BJ, Gertz RE, Gladstone RA, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016; 22(1): 60.e9–60.e29.
    CrossRefPubMed
  62. Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016; 62(9): 1119–1125.
    CrossRefPubMed
  63. Mendes RE, Hollingsworth RC, Costello A, et al. Noninvasive Streptococcus pneumoniae serotypes recovered from hospitalized adult patients in the United States in 2009 to 2012. Antimicrob Agents Chemother. 2015; 59(9): 5595–5601.
    CrossRefPubMed
  64. Oligbu G, Collins S, Sheppard CL, et al. Childhood deaths attributable to invasive pneumococcal disease in England and wales, 2006-2014. Clin Infect Dis. 2017; 65(2): 308–314.
    CrossRefPubMed
  65. van Hoek AJ, Andrews N, Waight PA, et al. Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes. PLoS One. 2012; 7(7): e39150.
    CrossRefPubMed
  66. Stanek RJ, Norton NB, Mufson MA. A 32-year study of the effect of pneumococcal vaccines on invasive streptococcus pneumoniae disease. Am J Med Sci. 2016; 352(6): 563–573.
    CrossRefPubMed
  67. Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 2009; 6(5): e1000081.
    CrossRefPubMed
  68. Kuchar E, Antczak A, Skoczyńska A, et al. Pneumococcal vaccination among adults – updated Polish recommendations. Family Medicine & Primary Care Review. 2022; 24(3): 285–291.
    CrossRef
  69. Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(4): 109–117.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2024 Via Medica Regulations Cookie policy Privacy Statement Legal Note